Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -21.83M | -31.30M | -35.04M | -58.49M | -56.22M |
| Total Depreciation and Amortization | 1.34M | 1.39M | 1.54M | 1.59M | 1.63M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.61M | 754.00K | 3.38M | 23.24M | 8.31M |
| Change in Net Operating Assets | -42.71M | -27.16M | 25.13M | 16.50M | 32.95M |
| Cash from Operations | -60.60M | -56.31M | -4.99M | -17.15M | -13.33M |
| Capital Expenditure | -670.00K | -1.05M | -518.00K | -429.00K | -438.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -670.00K | -1.05M | -518.00K | -429.00K | -438.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -7.00K |
| Issuance of Common Stock | 124.65M | 167.52M | 135.09M | 60.40M | 60.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -48.87M | -48.87M | -47.32M | -285.00K | -- |
| Cash from Financing | 75.78M | 118.65M | 87.78M | 60.11M | 60.39M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.51M | 61.29M | 82.27M | 42.53M | 46.63M |